AbCellera's platform generates lumpy, milestone-dependent revenue, with quarterly revenue swinging from $44.9M in 2025Q4 to $4.0M in 2026Q2, while operating expenses remain elevated at ~$60M per quarter, leading to persistent net losses and negative free cash flow.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | -$0.18-9.8% vs -$0.16 | $4M-48.4% vs $8M |
Q2 2026 May 11, 2026 | -$0.14+36.4% vs -$0.22 | $8M+53.6% vs $5M |
Q1 2026 Feb 24, 2026 | -$0.03+83.3% vs -$0.18 | $45M+572.9% vs $7M |
Q4 2025 Nov 6, 2025 | -$0.19-11.8% vs -$0.17 | $9M+41.9% vs $6M |
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.
AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation, five have issued a buy recommendation and one
AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
Benchmark ABCL against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for AbCellera Biologics Inc. (ABCL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.88 | $3.63B | -22.04 | 160.56% | -248.83% | -17.49% | — | |
| $120.79 | $7.52B | -55.13 | 20.32% | -31.66% | -29.89% | — | |
| $3.52 | $1.85B | -4.02 | 26.92% | -697.13% | -47.85% | — | |
| $29.82 | $2.23B | -37.68 | 23.29% | -22.01% | -18.11% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $1.63 | $89.62M | -1.32 | 15.57% | -490.71% | -27.23% | — |
AbCellera Biologics Inc. (ABCL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
AbCellera Biologics Inc. (ABCL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Aug 10, 2026·SEC
Aug 7, 2026·SEC
Get notified when ABCL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AbCellera Biologics Inc. (ABCL) stock FAQ — growth, dividends, profitability & financials explained
AbCellera Biologics Inc. (ABCL) reported $66.2M in revenue over the trailing twelve months. Revenue was $75.1M in fiscal year 2025. That is 751% more than the $8.8M of fiscal year 2018.
AbCellera Biologics Inc. (ABCL) grew revenue by 101.3% over the trailing twelve months, compared with the twelve months before.
No. AbCellera Biologics Inc. (ABCL) reported a net loss of $164.7M over the trailing twelve months.
AbCellera Biologics Inc. (ABCL) had a return on equity (ROE) of -17.5% over the trailing twelve months. A negative ROE means the company lost money over the period.
AbCellera Biologics Inc. (ABCL) had negative free cash flow of $179.5M over the trailing twelve months.
